Crinetics Pharmaceuticals (CRNX) 7th Annual Evercore ISI HealthCONx Conference summary

Company overview and pipeline status

• Registrational stage company focused on endocrinology with all pipeline assets developed in-house.

• Lead program for acromegaly has NDA submitted, with a decision expected next September.

• Pipeline includes programs for carcinoid syndrome, congenital adrenal hyperplasia (CAH), Cushing's disease, and four additional molecules entering development.

• New first-in-human data expected from several molecules over the next 12-18 months.

• Ongoing investment in discovery programs and aim to build a global endocrinology company.

Atumelnant (CAH and Cushing's disease)

• Atumelnant is the first antagonist of ACTH, targeting stress hormone disorders.

• Phase I program for CAH is wrapping up, with data from three cohorts to be reported early 2025.

• Early open-label results showed rapid normalization of hormone levels in CAH and Cushing's patients.

• Safety profile has been favorable, with no major concerns; theoretical risk of hyperpigmentation considered minor.

• Data update timing shifted to avoid holiday period, not due to clinical issues.

Paltusotine (Carcinoid syndrome)

• Phase III trial design focuses on flushing as the primary endpoint, with diarrhea/bowel movement frequency as a key secondary.

• Study design agreed with FDA to address both major symptoms while maintaining statistical power.

• PFS will be measured but not as a controlled endpoint; external synthetic controls will be used for context.

• New NDC platform for neuroendocrine tumors aims to advance treatment beyond current SRLs and radiotherapies.